Peculiarities of pharmacotherapy of chronic heart failure with retained left ventricular efficiency and associated atrial fibrilation depending on the method of heart rhythm control
Abstract
Introduction. Only small studies in selected centers have examined the effect of rhythm control strategy, including catheter ablation, on major cardiovascular events, mortality in patients with long-term atrial fibrillation and concomitant chronic heart failure with preserved left ventricular ejection fraction and features of pharmacotherapy. The aim. To study the peculiarities of pharmacotherapy in patients with heart failure with preserved left ventricular ejection fraction and concomitant atrial fibrillation over a long period of observation, depending on the implementation of a rhythm control strategy: radiofrequency ablation or pharmacotherapy and their impact on endpoints. Materials and Methods. The study included 194 patients with a mean age of 59.3 ± 8.5 years with atrial fibrillation and concomitant heart failure with preserved left ventricular ejection fraction I–III of the NYHA functional class. Patients were divided into 2 groups: 136 patients who underwent radiofrequency ablation, and 58 patients in the control group who did not undergo intervention and continued antiarrhythmic pharmacotherapy. The patients were compared according to the main clinical and demographic indicators. An assessment was made of the characteristics of pharmacotherapy and different stages of observation by group and its impact on endpoints. Results. In the control group, the use of antiarrhythmic drugs other than amiodarone and oral anticoagulants at the baseline of the study was associated with the primary endpoint. The chance of its occurrence was 3.9 times higher among patients taking other antiarrhythmic drugs (odds ratio–3.949, 95 % confidence interval 1.198–13.013) and 1.8 times lower among patients taking anticoagulants (odds ratio - 0.556, 95 % confidence interval 0.399–0.965). In the ablation group, the chance of a primary endpoint event occurring was 3.1 times higher among patients taking diuretics at 2-year follow-up (odds ratio –3.130, 95 % confidence interval 1.111–8.824), and beta-blockers were associated with 3.4 times lower chance of these events (odds ratio – 0.296, 95 % confidence interval 0.128–0.688). In the ablation group, there was a statistically significant decrease in the percentage of patients requiring diuretics 2 years after inclusion in the study compared with the 3-month stage (p < 0.001) and the inclusion stage (p < 0.001). Conclusions. Long-term use of beta-blockers after intervention is associated with a reduced risk of primary endpoint events in the ablation group. Taking diuretics, beta-adrenergic receptors, and renin-angiotensin-aldosterone system inhibitors during the first 3 months after the intervention reduces the risk of atrial fibrillation recurrence in the long-term follow-up period in the ablation group.
Downloads
References
Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, et al. Rhythm Control versus Rate
Control for Atrial Fibrillation and Heart Failure. N Engl J Med 2008; 358: 2667–77. DOI: https://doi.org/10.1056/NEJMoa0708789
Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Hear Rhythm 2017; 14: e275–444. DOI: https://doi.org/10.1016/j.hrthm.2017.05.012
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. J Am Coll Cardiol 2019; 74: 104–32. DOI: https://doi.org/10.1016/j.jacc.2019.01.011
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with
the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020: 1–126. DOI: https://doi.org/10.1093/eurheartj/ehaa612
Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, et al. Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial. Circulation 2016; 133: 1637–44. DOI: https://doi.org/10.1161/CIRCULATIONAHA.115.019406
Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med 2018; 378: 417–27. DOI: https://doi.org/10.1056/nejmoa1707855
Chen C, Zhou X, Zhu M, Chen S, Chen J, Cai H, et al. Catheter ablation versus medical therapy
for patients with persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized controlled trials. J Interv Card Electrophysiol 2018; 52: 9–18. DOI: https://doi.org/10.1007/s10840-018-0349-8
Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med 2020;383:1305–16. DOI: https://doi.org/10.1056/nejmoa2019422
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021: 1–128. DOI: https://doi.org/10.1093/eurheartj/ehab368
Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, Silverstein AP, Noseworthy PA, et al. Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure. Circulation 2021; 143: 1377–90. DOI: https://doi.org/10.1161/CIRCULATIONAHA.120.050991
Rattka M, Pott A, Kühberger A, Weinmann K, Scharnbeck D, Stephan T, et al. Restoration of sinus rhythm by pulmonary vein isolation improves heart failure with preserved ejection fraction in atrial fibrillation patients. Europace 2020;22:1328–36. DOI: https://doi.org/10.1093/europace/euaa101
AlTurki A, Proietti R, Dawas A, Alturki H, Huynh T, Essebag V. Catheter ablation for atrial fibrillation in heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 2019; 19:18. DOI: https://doi.org/10.1186/s12872-019-0998-2
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. J Am Coll Cardiol 2014; 64: e1–76. DOI: https://doi.org/10.1016/j.jacc.2014.03.022
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37. DOI: https://doi.org/10.1093/eurheartj/ehw210
Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial: Fibrillation An update of the 2010 ESC Guidelines for the management of atrial fibrillation: Developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14: 1385–413. DOI: https://doi.org/10.1093/europace/eus305
Kotecha D, Piccini JP. Atrial fibrillation in heart failure: What should we do? Eur Heart J 2015;36:3250–7. DOI: https://doi.org/10.1093/eurheartj/ehv513
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016; 37: 2129–2200m. DOI: https://doi.org/10.1093/eurheartj/ehw128
Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for Heart Failure with Preserved Ejection Fraction. N Engl J Med 2014; 370: 1383–92. DOI: https://doi.org/10.1056/NEJMoa1313731
McMurray JJ V., Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart. Eur Heart J 2012; 33: 1787–847. DOI: https://doi.org/10.1093/eurheartj/ehs104
Kaitani K, Inoue K, Kobori A, Nakazawa Y, Ozawa T, Kurotobi T, et al. Efficacy of Antiarrhythmic Drugs Short-Term Use after Catheter Ablation for Atrial Fibrillation (EAST-AF) trial. Eur Heart J 2016; 37: 610–8. DOI: https://doi.org/10.1093/eurheartj/ehv501
Al-Jazairi MIH, Nguyen B-O, De With RR, Smit MD, Weijs B, Hobbelt AH, et al. Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 study. EP Eur 2021; 23: 1359–68. DOI: https://doi.org/10.1093/europace/euab062
Duytschaever M, Demolder A, Phlips T, Sarkozy A, El Haddad M, Taghji P, et al. P ulm O nary vein isolation W ith vs. without continued antiarrhythmic D rug tr e atment in subjects with R ecurrent A trial F ibrillation (POWDER AF): Results from a multicentre randomized trial. Eur Heart J 2018; 39: 1429–37. DOI: https://doi.org/10.1093/eurheartj/ehx666
Nguyen B-O, Crijns HJGM, Tijssen JGP, Geelhoed B, Hobbelt AH, Hemels MEW, et al. Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial
fibrillation and heart failure: data of the RACE 3 trial. EP Eur 2021; 3: 1–11. DOI: https://doi.org/10.1093/europace/euab270
Kagawa Y, Fujii E, Fujita S, Ito M. Association between left atrial reverse remodeling and maintenance of sinus rhythm after catheter ablation of persistent atrial fibrillation. Heart Vessels 2020; 35: 239–45. DOI: https://doi.org/10.1007/s00380-019-01475-1
Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2021; 384: 1921–30. DOI: https://doi.org/10.1056/nejmoa1901281
Cikes M, Claggett B, Shah AM, Desai AS, Lewis EF, Shah SJ, et al. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial. JACC Hear Fail 2018;6:689–97. DOI: https://doi.org/10.1016/j.jchf.2018.05.005
Neefs J, van den Berg NWE, Limpens J, Berger WR, Boekholdt SM, Sanders P, et al. Aldosterone Pathway Blockade to Prevent Atrial Fibrillation: A Systematic Review and Meta-Analysis. Int J Cardiol 2017; 231: 155–61. DOI: https://doi.org/10.1016/j.ijcard.2016.12.029
Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q, et al. Perioperative Rosuvastatin in Cardiac Surgery. N Engl J Med 2016; 374: 1744–53. DOI: https://doi.org/10.1056/NEJMoa1507750
Humphries KH, Lee M, Sheldon R, Ramanathan K, Dorian P, Green M, et al. Statin use and
recurrence of atrial fibrillation after successful cardioversion. Am Heart J 2007; 154: 908–13. DOI: https://doi.org/10.1016/j.ahj.2007.07.015
The Journal of V. N. Karazin Kharkiv National University, series Medicine has following copyright terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
